Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath.
Francois-Xaxier Mahon
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; Novartis
Michele Baccarani
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Michael J. Mauro
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Timothy P. Hughes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis
Giuseppe Saglio
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Michael Savona
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Incyte
Other Remuneration - Karyopharm Therapeutics
Tomasz K. Szczudlo
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Hans D. Menssen
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Christopher Hunt Keir
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Claudia Walasek
Employment or Leadership Position - Novartis
Andreas Hochhaus
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis